KR101008796B1 - Functional food composition for alleviating or preventing essential tremor - Google Patents
Functional food composition for alleviating or preventing essential tremor Download PDFInfo
- Publication number
- KR101008796B1 KR101008796B1 KR1020080041074A KR20080041074A KR101008796B1 KR 101008796 B1 KR101008796 B1 KR 101008796B1 KR 1020080041074 A KR1020080041074 A KR 1020080041074A KR 20080041074 A KR20080041074 A KR 20080041074A KR 101008796 B1 KR101008796 B1 KR 101008796B1
- Authority
- KR
- South Korea
- Prior art keywords
- food composition
- egg yolk
- functional food
- essential
- yolk oil
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 235000013376 functional food Nutrition 0.000 title claims abstract description 9
- 201000006517 essential tremor Diseases 0.000 title abstract description 14
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 37
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 26
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 26
- 235000013345 egg yolk Nutrition 0.000 claims abstract description 26
- 239000009429 Ginkgo biloba extract Substances 0.000 claims abstract description 20
- 230000006872 improvement Effects 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 229940068052 ginkgo biloba extract Drugs 0.000 claims description 11
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 235000021395 porridge Nutrition 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 4
- 206010012335 Dependence Diseases 0.000 abstract description 2
- 239000003381 stabilizer Substances 0.000 abstract description 2
- 230000000087 stabilizing effect Effects 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 239000003921 oil Substances 0.000 description 27
- 206010044565 Tremor Diseases 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 11
- 235000013601 eggs Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 235000008100 Ginkgo biloba Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000036280 sedation Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000002956 ash Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 229960004232 linoleic acid Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 241000218628 Ginkgo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000013605 boiled eggs Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229940032702 ginkgo biloba extract 500 mg Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 231100000878 neurological injury Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021264 seasoned food Nutrition 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L15/00—Egg products; Preparation or treatment thereof
- A23L15/30—Addition of substances other than those covered by A23L15/20 – A23L15/25
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2122—Gingko Biloba
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
본 발명은 난황유를 유효성분으로 함유하는 본태성 진전 개선 및 예방용 기능성 식품조성물을 제공한다. 본 발명에 따른 기능성 식품조성물은 본태성 진전의 개선 및 예방에 유용한 효과를 가지며, 알코올, 신경안정제 등에서 나타나는 과도한 안정작용, 중독증상 등의 독성 및 부작용을 나타내지 않아 장기간 섭취시에도 안심하고 사용할 수 있다는 장점을 갖는다.The present invention provides a functional food composition for improving and preventing essential tremor containing egg yolk oil as an active ingredient. Functional food composition according to the present invention has a useful effect in the improvement and prevention of essential progress, and does not show the toxicity and side effects such as excessive stabilizing action, addiction symptoms such as alcohol, neuro stabilizers, etc. Has an advantage.
난황유, 은행잎 추출물, 본태성 진전 Egg yolk oil, ginkgo leaf extract, essential progress
Description
본 발명은 본태성 진전 개선 및 예방용 기능성 식품조성물에 관한 것이다.The present invention relates to a functional food composition for improving and preventing essential tremor.
본태성 진전이란 떨림을 일으킬 만한 특별한 이유 없이 신체의 일부가 떨리는 증상을 의미한다. 떨림이 나타나는 가장 흔한 부위는 손이며, 떨림은 불수의적인 근육의 수축으로 인하여 앞뒤로 움직이는 것으로 떨림의 강도는 사람마다 매우 다양하며 시간에 따라 다를 수 있다.Essential tremor refers to the trembling of part of the body without any particular reason for causing trembling. The most common site of tremor is the hand, and tremors move back and forth due to involuntary muscle contractions. The intensity of tremor varies greatly from person to person and can vary over time.
본태성 진전은 전체인구의 0.3%~1.7%, 40세 이상에서는 5.5%, 65세 이상에서는 10.2%로, 높은 발병률을 보이고 있으며, 진전의 정도에 따라 다르겠지만 본태성 진전은 일상 생활에서 심각한 신체적, 심리적 장애를 가져오기도 한다.Essential progress is 0.3% to 1.7% of the total population, 5.5% over 40 years old, 10.2% over 65 years old, and high incidence rates, depending on the degree of progression. This can lead to psychological disorders.
본태성 진전은 크게, 혈통성(flamilial) 진전, 협의의 본태성(essential) 진전 및 고령성(senile) 진전(tremor)으로 구분한다. 혈통성 진전은 가족력이 있는 진전으로, 유전되는 경향을 나타내며, 유년기부터 시작될 수 있으나, 전형적으로 성년기에 시작되고 평생 지속된다. 협의의 본태성 진전은 성년 초기에 시작하고 지속되는 특발성 진전으로, 유전적 패턴이 명백하지 않은 본태성 진전을 의미한다. 고령성 진전은 진전이 노후에 시작된 것이 명백한 것을 의미한다. 생리적 측면에서 각각의 진전은 쉽사리 구별되지 않으며, 포괄적으로 본태성 진전으로 총칭한다.Essential progress is largely divided into flamilial progression, consultation essential progression, and senile tremor. Pediatric progression is a family history, which tends to be inherited and can begin in childhood, but typically begins in adulthood and lasts a lifetime. Essential progress in consultations is idiopathic progress that begins and continues early in adulthood, meaning essential progress where genetic patterns are not evident. Aging progress means that progress is evident in old age. In physiological terms, each progression is not easily distinguished and is collectively referred to collectively as essential progression.
종래에는 본태성 진전을 개선하기 위해 알콜을 자가적으로 사용하였으나, 알콜의 사용은 알콜중독의 염려가 있다.In the past, alcohol was used by itself to improve essential progress, but the use of alcohol is a concern for alcoholism.
또한, 벤조디아제핀, 바비투레이트 등의 진정제를 본태성 진전을 개선하기 위해 사용할 수 있으나, 이 역시 남용의 문제와 지나치게 진정효과를 나타내게 되어 실생활에 어려움이 있을 수 있다는 문제점이 있다.In addition, although sedatives such as benzodiazepines and barbiturates may be used to improve essential tremor, this also has problems of abuse and difficulty in real life due to excessively calming effects.
따라서, 남용의 염려가 없고, 과도한 진정효과 등의 부작용을 나타내지 않으면서, 본태성 진전을 개선시킬 수 있는 조성물의 개발이 필요하다.Therefore, there is a need for the development of a composition capable of improving essential progress without fear of abuse and without exhibiting side effects such as excessive sedation effects.
한편, 난황유는 조류 알의 난황(노른자)에서 추출된 유상의 추출물이며, 난유, 계란기름, 계란유 등으로 불리운다.On the other hand, egg yolk oil is an oily extract extracted from egg yolk (yolk) of algae eggs, and is called egg oil, egg oil, egg oil and the like.
난황유는 지질, 비타민 A, 비타민 E, 리놀산 등을 함유하는 것으로 알려져 있으며, 지질은 중성지질, 인지질, 스테롤 등으로 구성되는 것으로 알려져 있다.Egg yolk oil is known to contain lipids, vitamin A, vitamin E, linoleic acid and the like, and lipids are known to be composed of neutral lipids, phospholipids, sterols and the like.
예로부터, 난황유는 중풍, 심장질환, 고혈압, 이질, 천식, 무좀, 탈항, 치질, 자양강장 등에 효과가 있는 것으로 알려져 민간요법으로 사용되어 왔다.Since ancient times, egg yolk oil has been known to be effective in stroke, heart disease, high blood pressure, dysentery, asthma, athlete's foot, anti-hanging, hemorrhoids, nourishing tonic, and has been used as a folk remedy.
본 발명자는 난황유가 본태성진전을 개선시키는 작용을 나타냄을 발견하여, 본 발명을 완성하였다.The present inventors have found that yolk yolk oil has an effect of improving essential tremor, thus completing the present invention.
본 발명이 해결하고자 하는 과제는 장기사용이 가능하며, 본태성 진전을 개선 및 예방할 수 있는 기능성 식품조성물을 제공하는 것이다.The problem to be solved by the present invention is to provide a functional food composition capable of long-term use, which can improve and prevent essential progress.
본 발명은 난황유를 유효성분으로 함유하는 본태성 진전 개선 및 예방용 기능성 식품조성물을 제공한다.The present invention provides a functional food composition for improving and preventing essential tremor containing egg yolk oil as an active ingredient.
상기 난황유는 조류의 알로부터 추출된 유상물질로, 난황유에는 레시틴, 인지질, 비타민 A, 비타민 E, 및 리놀산 등이 함유되어 있다. 상기 조류는 닭일 수 있다.The egg yolk oil is an oily material extracted from algae eggs, and yolk oil contains lecithin, phospholipids, vitamin A, vitamin E, and linoleic acid. The bird may be a chicken.
상기 난황유는 삶은 계란의 노른자를 태워서 난황유를 추출하는 소초법, 별도의 용매를 사용하여 난황유를 추출하는 용매추출법, 착유방식에 의한 추출법 등에 의해 추출된 것일 수 있다. 예를 들어, 일본 특허 공개공보 평 1-5474호, 대한민국 공개특허 제87-6843호, 공개특허 제92-11388호, 공고특허특1995-14959호 등에 기술된 방법을 이용하여 제조된 것일 수 있다.The egg yolk oil may be extracted by burning the yolk of the boiled egg by using a cowweed method for extracting egg yolk oil, a solvent extraction method for extracting egg yolk oil using a separate solvent, or an extraction method using a milking method. For example, it may be prepared using the method described in Japanese Patent Application Laid-Open No. 1-5474, Korean Patent Publication No. 87-6843, Korean Patent Publication No. 92-11388, Japanese Patent Application Publication No. 199595959 .
상기 본태성 진전은 혈통성 진전, 협의의 본태성 진전, 및 고령성 진전을 포함하는 개념이다. 즉, 유전적 요인을 갖는 혈통성 진전, 유전적 요인이 명백하지 않은 협의의 본태성 진전, 및 진전이 노후에 시작된 것이 명백한 고령성 진전을 모두 포함한다. 상기 진전은 손떨림 즉 수전증을 포함한다.The essential tremor is a concept including a pedigree tremor, a consensus essential tremor, and an aging tremor. That is, it includes both lineage progression with a genetic factor, essential progression of consultation where the genetic factor is not obvious, and aging progression where the progression is evident in old age. The tremor includes hand shake, or hydration.
본 발명의 조성물은 은행잎 추출물을 추가로 함유할 수 있다.The composition of the present invention may further contain a ginkgo leaf extract.
상기 은행잎 추출물은 시중에 판매되는 것, 또는 열수추출 등 당업계에 알려진 추출공정을 이용하여 제조된 것일 수 있다. 예를 들어, 은행잎 추출액 제조는 일본 특허공고 소 46-28091호, 일본특허공고 소 49-27323호, 또는 대한민국 특허공고 제90-5318호, 제90-5319호에 기술된 방법 등을 이용하여 제조된 것일 수 있다.The ginkgo leaf extract may be one that is commercially available, or may be prepared using an extraction process known in the art, such as hot water extraction. For example, ginkgo biloba extract is prepared using the methods described in Japanese Patent Publication No. 46-28091, Japanese Patent Publication No. 49-27323, or Korean Patent Publication Nos. 90-5318 and 90-5319. It may have been.
본 발명의 조성물에 추가로 함유되는 은행잎 추출물은 물(정제수), 메탄올, 에탄올, 또는/및 아세톤 등으로 추출된 것일 수 있다.The ginkgo leaf extract further contained in the composition of the present invention may be extracted with water (purified water), methanol, ethanol, and / or acetone.
상기 조성물은 난황유 100중량부에 대하여 은행잎 추출물 1~100중량부를 함유할 수 있다. 상기 비율에서 본태성 진전의 개선효과가 뛰어나다.The composition may contain 1 to 100 parts by weight of ginkgo biloba extract based on 100 parts by weight of egg yolk oil. The ratio is excellent in improving the essential tremor.
본 발명의 조성물은 식품분야에서 허용되는 담체를 추가로 포함할 수 있다. 용액, 현탁액 등의 액상 경구 제제의 경우 적절한 담체 및 첨가제는 물, 글리콜, 오일, 알콜, 향미제, 방부제, 계면활성제, 또는 착색제 등을 포함하고, 분말, 캡슐, 정제 등의 고형 경구 제제의 경우 적절한 담체 및 첨가제는 전분, 당, 희석제, 결합제, 활택제, 붕해제 등을 포함한다.The composition of the present invention may further comprise a carrier acceptable in the food field. In the case of liquid oral preparations such as solutions, suspensions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, surfactants, or colorants, and in the case of solid oral preparations such as powders, capsules, tablets, etc. Suitable carriers and additives include starch, sugars, diluents, binders, lubricants, disintegrants and the like.
본 발명의 조성물의 제제 형태는 과립제, 산제, 정제, 피복정, 캡슐제, 액제, 시럽, 즙, 또는 현탁제 등이 될 수 있다.Formulation forms of the compositions of the present invention may be granules, powders, tablets, coated tablets, capsules, solutions, syrups, juices, suspensions and the like.
본 발명의 조성물에 있어서, 활성성분의 투여량은 체중 60kg 성인기준으로 1회 섭취량 난황유 1~10g 및 은행잎 추출물 0.1~1g의 범위 내에서 조절할 수 있으며, 1일 3회 섭취할 수 있다. 다만, 투여될 최적의 섭취량은 당업자에 의해 쉽게 결정될 수 있으며, 질환의 종류, 증세의 정도, 조성물에 함유된 유효성분 및 다른 성분의 함량, 제형의 종류, 및 섭취자의 연령, 체중, 일반 건강 상태, 성별 및 식 이, 투여 시간, 및 조성물의 분비율, 섭취기간, 동시 사용되는 식품, 약물을 비롯한 다양한 인자에 따라 조절될 수 있다.In the composition of the present invention, the dosage of the active ingredient can be adjusted within the range of 1 ~ 10g egg yolk oil and 0.1 ~ 1g of ginkgo biloba extract per body weight 60kg adult basis, can be ingested three times a day. However, the optimum intake to be administered can be easily determined by those skilled in the art, the type of disease, the extent of symptoms, the amount of active ingredients and other ingredients contained in the composition, the type of formulation, and the age, weight, general health of the intake It can be adjusted according to various factors including the sex, diet, time of administration, and ratio of composition, duration of ingestion, food used concurrently, and drug.
본 발명의 조성물의 제형은 식품분야의 통상적인 방법에 따라 제조하며, 담체와 함께 건조한 후 캡슐화하거나 기타 정제, 과립, 분말 외에 음료, 죽 등의 형태로 제형화할 수 있으며, 상기 기재한 것 외에도 모든 식품 형태로 제조 가능하다.The formulations of the compositions of the present invention may be prepared according to conventional methods in the food field, and may be encapsulated after drying with a carrier, or may be formulated in the form of beverages, porridges, etc. in addition to other tablets, granules, and powders. It can be manufactured in food form.
즉, 본 발명의 조성물은 액제, 산제, 과립제, 정제, 캡슐제, 현탁제, 에멀젼, 시럽, 및 죽 등의 다양한 경구로 섭취할 수 있는 경구형 제형으로 제조될 수 있으며, 과자류, 유가공품류, 면류, 다류, 음료류, 건강보조식품류, 또는 조미식품류의 제품 형태로 제조될 수 있다.That is, the composition of the present invention can be prepared in various orally ingestible oral dosage forms such as liquids, powders, granules, tablets, capsules, suspensions, emulsions, syrups, and porridges, confectionery, dairy products, It may be prepared in the form of a product of noodles, teas, beverages, dietary supplements, or seasoned foods.
본 발명의 식품조성물은 본태성 진전의 개선 및 예방에 유용한 효과를 갖는다. 또한, 알코올, 신경안정제 등에서 나타나는 과도한 안정작용, 중독증상 등의 독성 및 부작용을 나타내지 않아 장기간 사용시에도 안심하고 사용할 수 있다.The food composition of the present invention has a useful effect in improving and preventing essential tremor. In addition, it does not show the toxicity and side effects such as excessive stabilizing action, addiction symptoms such as alcohol, neuro-stabilizers can be used with confidence even in long-term use.
본 발명의 이해를 돕기 위하여 실시예를 제시한다. 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 실시예에 의해 본 발명의 내용이 한정되는 것은 아니다.Examples are provided to help understand the present invention. The following examples are merely provided to more easily understand the present invention, but the contents of the present invention are not limited by the examples.
<제조예 1> 난황유의 제조Preparation Example 1 Preparation of Egg Yolk
계란을 100℃ 끓는 물에서 15분간 삶은 후, 계란의 껍질과 난백은 제거하고 노른자를 준비하였다. 스텐레스 재질 용기에 노른자 1kg을 넣고 으깬 후, 100~300℃의 온도로 5~10분 가열하면 노른자가 부글거리며 검게 타고 재가 되면서 마지막으로 유상으로 된 난황유가 형성되었다. 재 등의 탄화된 성분을 제거하고 유상의 난황유를 별도 용기에 채취하였다. 1kg의 계란 노른자 기준으로 50g의 난황유를 얻었다.After the eggs were boiled in boiling water at 100 ° C. for 15 minutes, the egg shells and egg whites were removed and the yolks were prepared. After crushing 1kg of yolk into a stainless steel container and heating it for 5-10 minutes at a temperature of 100 ~ 300 ℃, the yolk swelled and blacked to ashes. Carbonized components such as ash were removed and oily yolk oil was collected in a separate container. 50g of egg yolk oil was obtained based on 1 kg of egg yolk.
<제조예 2> 난황유와 은행잎 추출물 혼합액의 제조Preparation Example 2 Preparation of Egg Yolk Oil and Ginkgo Leaf Extract Mixture
1) 은행잎 추출물의 제조1) Preparation of Ginkgo Leaf Extract
은행잎을 깨끗이 세척하고 잘게 절단한 후, 은행잎 100중량부에 대하여 정제수 400중량부를 사용하여 95℃에서 4시간 동안 1차 추출한 후, 냉각시키지 않고 뜨거운 상태에서 여과지(와트만사)를 이용하여 여과하고, 여과 후 남은 고형분에 다시 정제수 200중량부를 추가하여 상기와 동일한 조건에서 2차 추출하였다. 이 두가지 추출액을 여과하여 고형분을 제거한 후, 여과액을 가열 농축하였다. 1kg의 은행잎을 기준으로 350g의 농축 추출물을 얻었다.After the ginkgo leaves were washed and cut finely, the extract was first extracted at 95 ° C. for 4 hours using 400 parts by weight of purified water with respect to 100 parts by weight of ginkgo biloba, and then filtered using a filter paper (Watman) without heating, 200 parts by weight of purified water was added to the solids remaining after the filtration, and the mixture was extracted secondly under the same conditions as described above. The two extracts were filtered to remove solids, and then the filtrate was concentrated by heating. 350 g of concentrated extract was obtained based on 1 kg of ginkgo biloba leaves.
2) 난황유와 은행잎 추출물 혼합액의 제조2) Preparation of Egg Yolk Oil and Ginkgo Leaf Extract Mixture
제조예 1의 난황유 100중량부에 대하여 상기 1)의 은행잎 추출물 10중량부의 비율로 혼합하여 난황유 및 은행잎 추출물 혼합액을 제조하였다.100 parts by weight of egg yolk oil of Preparation Example 1 was mixed at a ratio of 10 parts by weight of the ginkgo biloba extract of 1) to prepare a mixture of egg yolk oil and ginkgo biloba extract.
<실시예 1> 본 발명 조성물의 본태성 진전 개선 효과 확인Example 1 Confirmation of the essential improvement effect of the composition of the present invention
본 발명 조성물의 본태성 진전 개선 효과를 알아보기 위하여, 자가측정척도를 이용한 본태성 진전 개선 효과 확인 시험을 이하의 방법으로 수행하였다.In order to investigate the effect of improving the essential tremor of the composition of the present invention, a test for confirming the essential tremor improvement effect using a self-measurement scale was performed by the following method.
손떨림 증상이 6개월 이상 지속되는 30~75세 성인 남,녀 15명을 3개의 군으로 나누어 제조예 1의 난황유 5g, 제조예 2의 1)에서 제조된 은행잎 추출물 500mg, 제조예 2의 2)에서 제조된 난황유와 은행잎 추출물 혼합액 5.5g을 열흘간 1일 3회 섭취하도록 하였다.Ginkgo biloba extract 500mg prepared in 1) of yolk oil of Preparation Example 1, Preparation Example 2, dividing 15 male and female adults aged 30-75 years with symptoms of shaking for more than 6 months, 3) 5.5g of egg yolk oil and ginkgo biloba extract extract prepared in 10 days was to be taken three times a day.
(단, 손떨림이 갑자기 발생하였거나, 항진된 생리학적 진전이나, 진전을 유발할 수 있는 약물에 관련이 있는 경우, 진전 발생 3개월 이전에 신경학적 손상을 받은 경우, 혹은 임상적으로 심인성 원인에 의한 진전증이 의심되는 경우는 제외하였다.)(However, if the shaking occurs suddenly, is associated with an increased physiological progression, or a drug that can cause tremor, a neurological injury 3 months before the tremor, or a clinically psychological cause of tremor) This case was excluded.)
진전(손떨림)의 평가는 '본태성 진전증의 임상 양상'(대한신경과학회지 17(4):528~533, 1999)에 제시된 자가 측정 척도를 이용하였다. 이 척도는 진정증의 정도에 따라 크게 6가지 단계로 나누어, 매일 환자들로 하여금 직접 점수를 기록하게 하여 진전증의 변화를 평가하기 위한 것이다.The assessment of tremor was carried out using the self-measurement scales presented in 'Clinical Aspects of Essential Tremor' (Korean Journal of Neurology 17 (4): 528 ~ 533, 1999). This scale is divided into six levels, depending on the degree of sedation, to allow patients to record their own scores daily to assess changes in tremor.
진전증 자가 측정 척도는 이하의 표 1에 나타내었다.Tremor self-measurement scales are shown in Table 1 below.
또한, 하기 수학식 1에 의하여 진전 정도의 평균값을 계산하였으며, 그 결과를 표 2에 나타내었다.In addition, the average value of the degree of progress was calculated by the following equation 1, the results are shown in Table 2.
섭취군
Intake group
투여전
Before administration
투여 후 5일 경과
5 days after dosing
투여 후 10일 경과
10 days after dosing
난황유
Egg yolk
96
96
32
32
8
8
은행잎추출물
Ginkgo Leaf Extract
92
92
88
88
80
80
난황유+은행잎추출물
Egg Yolk + Ginkgo Biloba Extract
96
96
28
28
4
4
상기 표 2에 나타난 바와 같이 난황유 섭취군의 경우는 손떨림 증세 개선효과가 뚜렷하게 나타났다. 은행잎 추출물만을 섭취한 경우에는 손떨림 증세 개선 경향이 크지 않았다. 난황유에 은행잎 추출물을 혼합하여 섭취한 후 10일 경과시에는 난황유 단독 섭취에 비하여 손떨림 증세 개선효과가 수치상으로 2배가 되는 것으로 나타났다.As shown in Table 2, in the case of the yolk-milk-ingestion group, the effect of improving hand shaking was apparent. When only ginkgo biloba extract was ingested, there was no tendency to improve image stabilization. After 10 days of mixing ginkgo biloba extract with egg yolk oil, the improvement of the image stabilization effect was doubled numerically compared to yolk oil alone.
또한, 난황유 또는/및 은행잎추출물을 섭취한 모두에게서 지나친 진정작용 등의 부작용은 전혀 나타나지 않았다.In addition, no side effects such as excessive sedation were observed in all who consumed yolk oil and / or ginkgo biloba extract.
따라서, 본 발명의 조성물은 본태성 진전 개선 및 예방효과가 뛰어나며, 부작용이 나타나지 않아 장기간 사용이 가능함을 알 수 있다.Therefore, the composition of the present invention is excellent in the improvement and prevention effect of essential progress, it can be seen that no side effects can be used for a long time.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080041074A KR101008796B1 (en) | 2008-05-01 | 2008-05-01 | Functional food composition for alleviating or preventing essential tremor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080041074A KR101008796B1 (en) | 2008-05-01 | 2008-05-01 | Functional food composition for alleviating or preventing essential tremor |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090115300A KR20090115300A (en) | 2009-11-05 |
KR101008796B1 true KR101008796B1 (en) | 2011-01-14 |
Family
ID=41556447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080041074A KR101008796B1 (en) | 2008-05-01 | 2008-05-01 | Functional food composition for alleviating or preventing essential tremor |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101008796B1 (en) |
-
2008
- 2008-05-01 KR KR1020080041074A patent/KR101008796B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20090115300A (en) | 2009-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5284097B2 (en) | Anti-obesity composition | |
US6582735B2 (en) | Compositions and methods of use for extracts of magnoliaceae plants | |
US8709503B2 (en) | Use of cocoa extract | |
JP2009511468A5 (en) | ||
US20100184666A1 (en) | Novel use of cocoa extract | |
KR20060047367A (en) | Composition trapping radicals in organism | |
RU2701567C1 (en) | Agent possessing hepatoprotective activity | |
JP5064652B2 (en) | Diabetes prevention and treatment composition and health food containing active ingredients thereof | |
JP2008266223A (en) | Formulation for ameliorating excessive sensitivity to cold | |
EP2603211B1 (en) | Composition for treating hyperlipidemia | |
US8765191B2 (en) | Cocoa extracts for use in providing skin benefits | |
JP2007145825A (en) | Composition for brain function improvement | |
KR101008796B1 (en) | Functional food composition for alleviating or preventing essential tremor | |
KR102439576B1 (en) | Composition of Nutrient Delivery System for Improving Brain Function | |
KR101511364B1 (en) | Herbal Extract Composition for Prevention or Treatment of Obesity and Metabolic Syndrome Using Herbal Extract | |
WO2005070435A1 (en) | Agent for improving dynamic eyesight | |
KR101379368B1 (en) | Composition for treating alcohol intoxication containing fructus xanthii extracts and method of preparing the extracts | |
JP2022124984A (en) | Lipase activity inhibitor and use thereof | |
JP3106565B2 (en) | Chlorella preparation containing ginkgo biloba extract | |
KR100679698B1 (en) | An extract of Pterocarya paliurus with blood sugar level-lowering activity and functional food comprising the same | |
KR100596318B1 (en) | Healthy foods containing butterbur extract for memory ability improvement | |
JPH09187248A (en) | Antiallergic food | |
CN117042784A (en) | Composition for improving sleep quality | |
KR20230026790A (en) | Pharmaceutical compositions that contain an extract ofPelvetia siliquosa for the prevention or the treatmentof liver disease, diabetes and diabetic complications | |
JP2004359606A (en) | Composition suppressing absorption of sugar and alcohol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140107 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150112 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160617 Year of fee payment: 6 |
|
LAPS | Lapse due to unpaid annual fee |